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THE CHALLENGE OF ASSESSING HEALTH TECHNOLOGIES EARLY IN THE
DEVELOPMENT. SYSTEMATIC LITERATURE REVIEW OF METHODS IN USE
Markiewicz K, van Til J, IJzerman MJ
University of Twente, Enschede, The Netherlands
Medical devices are being developed continuously and their developers are under
pressure to provide better evaluations of their products. Early assessment gathers
the preliminary evidence to estimate clinical, financial, organizational, and social/
ethical consequences of a particular technology. It seems a useful tool in predicting
the potential of medical devices at the stage in which it can be adapted to fit the
environment or the environment can be prepared for the technology. If the poten-
tial is low, further development can also be stopped. Although early assessment is
recognized as an important part of medical device development process, there are
many uncertainties in its nature and regarding the methods that are being used for
its purpose. OBJECTIVE: To review different methods and their use in the early
assessment of medical technologies. METHODS: An extensive systematic litera-
ture review of different early assessment methods. The authors systematically
searched: computerised databases; published bibliographies of related topics; ci-
tations in articles reviewed; and references provided by colleagues. RESULTS: We
identified 40 studies that met the inclusion criteria. 18 papers were either system-
atic literature Reviews (5) or theoretical papers (13). 10 papers were addressing
specific applications of early assessment methodologies, and 12 papers were ad-
dressing theoretical concepts combined with examples. Those 22 articles were
analysed and categorised with regard to the stage of development of the technol-
ogy, innovation type, perspective and aims of the analysis. Aims, outcome and
uncertainties with regard to the outcome of the analysis were assessed.
CONCLUSIONS: There is a need to clarify and communicate the aims and value of
early assessment methods of medical devices to developers and policy makers, if
early assessment methods are to become an integrated part of early activities in
the development process.
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THE VALUE OF CHOICE IN A COLLECTIVELY FUNDED HEALTH SYSTEM: AN
EXTENDED ANALYTICAL APPROACH TO EXAMINE THE CONFLICT BETWEEN
DECISIONS AT INDIVIDUAL AND SOCIETAL LEVEL
Espinoza MA
University of York, Heslington, York, UK
Cost-effectiveness analysis is a well recognized tool to support decisions about
resource allocation in health care, particularly in the context of collectively funded
health systems. When a new technology is restricted based on cost-effectiveness
(because it is deemed too expensive relative to its expected benefits) a potential
conflict can arise between the social interests (i.e. maximization of the population
health subject to fixed budget constraint) and individuals who want to maximize
their own health or utility. It has been previously argued that decisions that con-
sider heterogeneity add value to the health care system. On the one hand, if a
centralized decision process is implemented (e.g. NICE in the UK), subgroup anal-
ysis is appropriate. On the other hand, if a decentralized process is to be imple-
mented, the effect of unrestricted choices on the social interests must be assessed.
I have recently presented an analytical approach to estimate the expected health
forgone (or gained) as a consequence of implementing a decentralized decision
process. In the simplest case it was assumed that social planners and patients
focus on the same metric of health, i.e. patients maximise health (for example,
QALYs) and social decision makers maximise net health (net QALYs). This piece of
work examines the case where patients choose according to a different maximand.
The analysis shows that if a single and different argument of the patient’s maxi-
mization function can be identified, the expected net health benefits forgone (or
gained) from implementing unrestricted choices can be estimated as an extension
of the base-case analysis. It also highlights the role of a robust estimation of the
joint distribution of potential outcomes, discussing gaps that require further re-
search. The contribution of this analysis for policy decisions about individualized
care is illustrated with a stylized numerical example.
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AN INTEGRATED FORMAL FRAMEWORK FOR REIMBURSEMENT, RESEARCH AND
PRICING DELIBERATIONS IN HEALTH TECHNOLOGY ASSESSMENT
Griffin S1, Spackman E2, Soares MO3, McKenna C3, Claxton K4
1University of York, York, North Yorkshire, UK, 2University of York, Heslington, North Yorkshire,
UK, 3University of York, York, UK, 4University of York, Heslington, York, UK
Reimbursement and research decisions about the utilisation of health care inter-
ventions can be formally characterised using methods for economic evaluation.
Reimbursement decisions are informed by establishing the expected cost-effec-
tiveness of the intervention. Research decisions are informed by establishing the
expected value of additional information (the cost of uncertainty). Price negotiation
can be used to alter conclusions about the benefits of reimbursement and the need
for further research. In practice each of these elements may be considered sepa-
rately, but they could routinely be combined within a single evaluation. Previous
research has shown (i) the impact of future changes on the payoff from reimburse-
ment in the presence of irrecoverable costs and uncertainty that will be resolved
over time, and; (ii) how the reimbursement and research decisions interact in
terms of the ability to acquire additional information and the impact of delay on
the payoffs and the size of the populations that can benefit. The objective of this
paper is to bring together established methods, using a consistent set of notation,
to describe a general algebraic framework. The aim is to show systematically how
irrecoverable costs, uncertainty that can be resolved through research and uncer-
tainty that will be resolved over time can be formally incorporated in an integrated
framework to estimate both cost-effectiveness and the value of further research
that reflects the interaction between the reimbursement and research decisions.
Furthermore we show how effective price negotiation would affect the payoff and
ranking of the alternative policy options. A simple numerical example is used to
demonstrate the application of this general algebraic framework and how the re-
sults might be presented to decision makers. The advantage of a single integrated
framework is that reimbursement, research and pricing decisions can be informed
simultaneously, transparently and consistently.
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INTERNAL AND EXTERNAL VALIDITY IN ECONOMIC MODELING:
CONSIDERATIONS BASED ON A PUBLISHED EXAMPLE
Porzsolt F
University of Ulm, Ulm, Germany
OBJECTIVES: Economic modeling is an established tool used for allocation of
health care resources. Modeling was designed to demonstrate the influence of
variables on defined outcomes (e.g. cost-effectiveness) in complex systems. Valid
information for health care decisions can be obtained if five types of bias can be
avoided: selection-, performance-, attrition-, detection-, and sampling-bias. In this
study the validity of results derived from economic modeling is investigated ad-
dressing these five types of possible biases. METHODS: A published economic
model of costs and benefits of drug treatment in mild-to-moderate Alzheimer’s
disease (Guo et al., J Med Econ 2010;13:641-654) was used for this analysis. Nine
questions were asked to confirm the validity of the obtained results. Internal va-
lidity was tested by checking the first four of the above types of bias, external
validity by checking for a possible sampling bias. RESULTS: The presented model is
flawed by absence of an explicit study question. Selection bias cannot be excluded
as the patient data were obtained from pooled clinical trials and other sources.
Performance bias is likely as the outcomes in patients extracted from pooled clin-
ical trials differed considerably to the outcomes of patients treated outside of trials.
A detection bias is likely as observed data were compared with extrapolated data.
Also the external validity of the study is likely to be impaired as the patients profiles
were not derived from real world conditions but from patients enrolled in two
clinical trials. CONCLUSIONS: This appraisal shows that phrasing a study question
is essential for selection of the appropriate study method. Economic modeling is
useful to discuss models and to generate hypotheses but always implies a high risk
of bias. Therefore, results from modeling should only be accepted when internal as
well as external validity of the used method has been confirmed.
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OPTIMIZING PUBLIC HEALTH DECISION OVER TIME: A DYNAMIC BUDGET
OPTIMIZATION MODEL WITH MULTIPLE CRITERIA DECISION MAKING
Ethgen O1, Topachevskyi O2, Connolly M3, Standaert B2
1University of Liege, Liege, Belgium, 2GlaxoSmithKline Vaccines, Wavre, Belgium, 3Global Market
Access Solutions, St Prex, Switzerland
To guide health care decision, modeling efforts have mainly focused on cost-effec-
tiveness appraisals (CEAs) between two mutually exclusive interventions. As CEAs
do not document the impact of interventions on health care budget, they are gen-
erally complemented with budget impact analysis (BIAs). BIAs provide financial
projections only and do not detail the beneficial health effect an intervention may
have on the population targeted. Additionally, decision makers may have different
and several competing preferences and priorities on what constitutes the popula-
tion health value of an intervention. A typical example is the public health impact
of large childhood vaccination campaigns. Reduction of incidence, prevalence,
hospitalizations, deaths, costs, etc. are the many criteria assessed by decision mak-
ers beyond the QALYs gained when they contemplate vaccination campaigns. In
this research, we design a transparent dynamic budget optimization model based
on a multi-criteria decision making framework. The model is a sequential multi-
birth cohort model with yearly cycle and adaptable time-horizon (from 3 years
onwards). Optimization is realized yearly based on the population outcomes
achieved the year before, the annual budget constraints and through different
combinations and weightings of decision preferences. Decision maker preferences
can be weighted on number of cases avoided, GP visits avoided, hospitalizations
avoided, length of in-hospital stay reduction, number of in-hospital beds avoided,
number of death avoided, Life-Years gain and QALYs gain. The model is intended
to address specific questions that usually emanate from decision makers con-
fronted with the introduction of mass vaccination campaigns: What is the yearly
budget needed to achieve specific public health goals? What are the yearly and
overall expected outcomes at the population level (i.e. the public health impact or
in others words, the return-on-investment in terms of public health benefit)?
Which intervention should be given additional (less) resources to maximize (mini-
mize) impact if the available budget is increased (decreased)?
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OPTIMAL SHOPPING: AN EVAUATION OF DECISION RULES IN COST-
EFFECTIVENESS ANALYSIS (CEA)
McKenna C1, Claxton K2
1University of York, York, UK, 2University of York, Heslington, York, UK
Standard decision rules in CEA are founded on a single objective to maximise
health subject to a single and exogenous budget constraint. In essence, this is a
well-specified constrained optimisation problem. The difficulty of using mathe-
matical programming (MP) solutions to inform the allocation problem is that the
informational demands are not feasible. However, it does provide an opportunity
to evaluate the performance of simple ex-ante decision rules that have been pro-
posed, some of which are being used to make decisions about health care technol-
ogies. Different decision rules are evaluated which compare: 1) the health gained
and forgone for a new technology based on an estimate of the cost-effectiveness
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threshold, and 2) the health effects of the new technology with the health effects of
those technologies which must be displaced to accommodate its additional costs.
The performance of each is evaluated through a simulation exercise, which using
shopping at the supermarket as an analogy to the health care system. An initial
basket of goods represents the initial allocation and specifies the budget constraint.
The task is to improve the contents of the basket by examining other things on the
shelves and applying one of the decision rules. Performance is measured by: 1) how
close each can get to the optimal basket (a MP solution), and 2) how quickly each
improves the initial basket. We explore when each decision rule performs at its
best and when one is likely to outperform the other. This includes: indivisibly of
technologies and programmes, size of the budget relative to programme costs, the
efficiency of exiting technologies; the type of information available to decision
makers and whether they are able to learn from examining more products. This
helps to identify where additional information (e.g., a better estimate of the thresh-
old) might be most valuable.
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THE VALUE OF PERSONALIZED MEDICINE: IT IS MORE ABOUT UNVEILING THE
PERFORMANCE OF THE COMPANION DIAGNOSTIC
Ethgen O
University of Liege, Liege, Belgium
Personalized medicine (PM) is notably typified by the development of companion
diagnostic tests to guide optimal treatment selection. PM has thus the potential to
dramatically improve patients’ outcomes and optimise allocation of resources.
However, very few attempts exist that transparently include diagnostic test per-
formance such as Sensitivity (Se) and Specificity (Sp) into cost-effectiveness and
budget impact models. This research proposes an analytical framework to unveil
diagnostic added-value according to different diagnostic performance scenario.
The framework is based on a decision tree and compares two hypothetical treat-
ments N vs. C. N is a new treatment associated with a companion diagnostic test T.
C is the current standard of care not associated with any test. T selects the likely
responding patients based on the presence (T) or absence (T) of a predictive sign
of response to N (a distinctive biomarker for instance). We demonstrate that it is
the prior prevalence of the sign within the target population coupled with the
expected effectiveness differential between N and C in true positive patients and
with the performance of the test (Se and Sp) that are the fundamental determi-
nants of the potential value of a PM strategy. An extension of the model to the case
of 2 competing PM strategies (and thus 2 competing tests) is shown. We conclude
that companion diagnostic test performance is key to achieve the promises of PM.
This analytical framework allows payers, HTA bodies and manufacturers to gauge
the potential value and financial impact of a PM strategy at all stage of its develop-
ment.
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ON THE PROBABILITY OF INTERTEMPORAL INDIFFERENCE
Parouty M1, Postma M2
1University of Groningen, Groningen, The Netherlands, 2Unit of PharmacoEpidemiology &
PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen , The
Netherlands
Issues on discounting health effects have spurred debates on appropriate decision
rules. Consensus is that empirically observed rates of time preference be incorpo-
rated in analysis. The latter, however, is known to suffer from cognitive limitations.
The human nervous system perceives how long sensory events last and the latter
impact on perceptual decision making which is the act of choosing from a set of
alternatives on the basis of available sensory evidence; in our case the indifference
balance between present and future consumption. Statistical tools for such pur-
poses are however scarce and normality assumptions often fail to hold. We there-
fore derive a stochastic distribution by maximum entropy principle(MaxEnt). A
MaxEnt distribution is one which best represents the current state of knowledge.
Furthermore, MaxEnt distributions minimize the amount of prior information built
into the distribution. Such distributions are usually sought by maximization of
entropy constrained on what is known. In our case, we assume that the expected
indifference amount at time t compared to an amount, y0, now is given by
E(Y(t))y0/w(t) where w(t) is a general time-inhomogeneous discount weight. With
that constraint and the usual probability constraints, we derive a maximum en-
tropy distribution for such a future amount. That is, we provide a closed-form
distribution of the probability that an individual is indifferent between some quan-
tity Y(t)y at time t and a quantity Y(0)y0 now given E(Y(t))y0/w(t).
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THE NEED TO CONDUCT FUTURE RESEARCH ON THE BENEFIT OF THE
PROSTATE SPECIFIC ANTIGEN SCREENING TEST USING THE VALUE OF
INFORMATION FRAMEWORK
Reese ES, Mullins CD
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: Prostate cancer (PC) is the second most common cancer in men
worldwide and the second leading cause of cancer deaths in men in the United
States. Recently, the prostate specific antigen (PSA) test used to screen and diag-
nosis PC has been questioned due to concerns regarding clinical utility and its
inability to accurately identify men with PC. This research aims to estimate the
Value of Information (VoI) of the PSA screening research and to determine whether
future PSA screening research should be focused on specific populations.
METHODS: This research uses the Minimal Modeling Approach (MMA) in order to
determine the expected value of information for PSA research. The population
expected value of information (pEVI) for racial (African Americans and non-African
Americans) and age (65-75 years, 76-85 years, 85 years) subgroups will be deter-
mined. Investigators will model survival based on published randomized con-
trolled trials of PSA screening and will use data from the Surveillance Epidemiology
and End-Result (SEER)-Medicare dataset for both survival and costs. Investigators
will structure analyses by modeling the net benefit of men who received a prostate
specific antigen screening exam between 2000 and 2007. RESUTS:VoI is recognized
for providing a framework for estimating the expected benefits of clinical research.
Due to the controversy surrounding the PSA screening test, patients and clinicians
are challenged when trying to make informed decisions regarding diagnosis and
treatment of PC.CONCLUSIONS:This research seeks to determine where the great-
est return on research investment would provide a more accurate evidence base for
PSA screening for PC.
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IDENTIFICATION AND TRANSLATION OF CULTURALLY BOUND TERMS IN
PATIENT REPORTED OUTCOME MEASURES
Simpson H, Two R, Verjee-Lorenz A, Clayson D
PharmaQuest Ltd, Banbury, UK
Patient reported outcome (PRO) measures typically undergo a precise and detailed
translation process which involves the input of translators, investigators, project
managers and developers in order to produce the most accurate and fluent trans-
lation possible. In order for the pooling of data from international clinical trials to
be possible, it is important that translations of a PRO measure mean the same to all
respondents, not just in terms of the phrasing, but also in terms of the intensity and
nuance of the phrases used. It is often the case that terms used frequently in PRO
measures will have a direct and literal translation into the target language. How-
ever, problems can occur when terms used in the source text are culturally bound
– i.e., when the direct translation of a term has a different meaning than that of the
source text, in terms of intensity or connotations, or is used in a different way. For
example, the term ‘frustrated’ has a direct translation in most languages; however,
this term has a stronger meaning in some countries and can refer to a mental
health issue. Issues can also arise when there is no equivalent of the source term in
the target language. We will discuss common terms, expressions and nuances that
are frequently used in PRO measures and how their meaning can be different
across varying languages and cultural backgrounds. We will examine how to pre-
empt these issues and how to avoid the mistranslation of culturally bound terms,
by discussing the importance of detailed concept elaboration documents, input
from the instrument developer, and in-depth pilot testing and cognitive debriefing.
By using these methods it is possible to accurately anticipate these potential issues
and explore alternative ways of conveying the intended meaning.
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THE VALUE OF FURTHER RESEARCH: THE ADDED VALUE OF INDIVIDUAL-
LEVEL DATA
Saramago P
University of York, York, North Yorkshire, UK
OBJECTIVES: Judgements based on average cost effectiveness estimates may dis-
guise sources of heterogeneity that should be reflected in decision making. Making
decisions considering between patient heterogeneity has been proved consistent
with an efficient use of limited resources. Although individual level data (IPD) is
often not available to inform decision models, these provide unbiased and more
precise estimates, particularly in the presence of heterogeneity. This paper seeks to
assess the added value of having access to IPD, compared to using aggregate data
(AD) only, in appropriately performing subgroup value of information analysis.
METHODS: This paper develops a framework that informs the understanding of
the implications of considering IPD when assessing the value of additional re-
search in the absence and in the presence of mutually exclusive population
subgroups. RESULTS: The developed framework explores the capabilities of the
available evidence (i.e. IPD and AD) in guiding and in quantifying the value of
further research in the absence and presence of subgroups. Issues around the
optimal number of subgroups and for which population subsets should further
research be undertaken are discussed. These exercises are supported by a moti-
vating example on the cost effectiveness of child accident prevention programmes.
CONCLUSIONS: The use of IPD rather than AD estimates may influence not only
the extent to which an appropriate understanding of existing heterogeneity is
attained, but, more importantly, it may shape approval decisions for particular
population subgroups and judgements of furtherresearch.
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WHAT IS THE ROLE OF EARLY HEALTH TECHNOLOGY ASSESSMENT OF
BIOMARKERS IN THE PRE-CLINICAL DEVELOPMENT PHASE? A REFLECTION ON
LESSONS LEARNED WITH MULTIPLE MYELOMA
Gaultney JG1, Redekop WK1, Sonneveld P2, Uyl-de Groot CA1
1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands,
2Erasmus Medical Center, Rotterdam, The Netherlands
OBJECTIVES: Biomarkers associated with treatment efficacy and safety can be used
to develop pharmacogenomic tests. However, translation of the evidence into clin-
ical practice is difficult due to barriers to development and the difficulty to dem-
onstrate clinical and economic utility. Health technology assessment (HTA) meth-
odology may be used to inform decisions at many points during the product
lifecycle. We assessed the role of HTA in the development phase of pharmacog-
enomic tests in multiple myeloma.METHODS: Early-Stage hta was conducted sep-
arately for two clinical applications of biomarkers: 1) a safety-based companion
diagnostic, and 2) a prognostic test. We reviewed the methods that were useful in
answering the questions about the health benefits and costs of the intervention
and comparators strategies in each scenario were reviewed. RESULTS: An evi-
dence-based approach was applied for both scenarios. Using literature reviews and
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